|
|
 |
 |
Business Integrity |
 |
 |
 |
 |
 |
Schering-Plough's Vision to "Earn Trust, Every Day" is supported by the company's strong emphasis on business integrity and compliance with laws and regulations impacting the company's global business operations. The company's "Leading with Integrity" compliance program includes a number of significant elements, including policies and procedures, training, auditing and monitoring, an anonymous reporting hotline, an investigations process, and application of discipline when appropriate. Education, training and communication are a prime focus of Schering-Plough's compliance program. All Schering-Plough employees receive regular training on compliance and the company's expectations for business integrity. Company policies coverage a wide range of topics and set the standards for employees' way of working with each other, as well as with physicians, government organizations and other stakeholders. The Global Compliance and Business Practices organization maintains the program and assures that it is appropriately implemented.
Schering-Plough regularly benchmarks its compliance program against its peers and leading companies in other industries and adjusts the program when necessary to accommodate the changing legal and regulatory environment.
Click here for a description of Schering-Plough's compliance program.
Click here for the Declaration of Compliance.
Click here for the Standards of Global Business Practices.
Click here for the Board of Directors Code of Business Conduct and Ethics.
|
 |
 |
|
 |
 |
 |
 |
 |
 |
| |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
 |
| |
Chairman and CEO:
Fred Hassan |
 |
| |
Number of employees:
55,000 |
 |
 |
| |
Net sales (2007):
$12.7 billion |
 |
 |
| |
Business operations in more than:
140 countries |
 |
| |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
 |
| |
R&D investment
(2007):
$2.9 billion |
 |
| |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
 |
|
 |
 |
 |
|